Fatty acid conjugation as used in Semaglutide and Retatrutide promotes reversible albumin binding that shields the peptide from enzymatic degradation and slows renal filtration, extending the half-life from minutes to days
Since the FDA declared the shortages over, these flexibilities are being revoked, prompting drug compounders and telemedicine companies to scramble to find solutions to continue sales
GLP-1 medications can cause side effects such as nausea, constipation, fatigue, reflux, or appetite changes, especially during dose escalation
Eli Lilly is actively exploring or partnering on solutions for this challenge, including Bimagrumab from Versanis Pharmaceuticals and LAE102 from Laekna
This promotes transition into the anagen (growth) phase
How can we avoid weight regain after stopping GLP-1 receptor agonists